Go Back
Available Until 2/3/2026

Pharmacotherapy Intensive Studies (Cert #L259006)

ACPE Numbers: Various – see listing below
Content Release Date: February 5, 2025
Expiration Date: February 3, 2026
Activity Type: Application-based
CE Credits: 6 contact hours
Activity Fee: $140 (ASHP member); $205 (non-member)

Activity Overview

These activities were presented as part of the 2024 Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting should not claim ACPE credit again.

The Intensive Studies Package is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pharmacotherapy. 

The Pharmacotherapy Intensive Studies Recertification Package consists of 4 activities (see table below) and provides up to 6.0 contact hours of continuing pharmacy education and/or recertification credit. 

These activities are part of the ASHP professional development program for BCPS recertification approved by BPS.

ACPE Provider with Commendation logo

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Uses and limitations of noninferiority trials
  • COPD management strategies
  • Risks and benefits of aspirin in cardiovascular diseases
  • Benefits and pitfalls of generative artificial intelligence in pharmacy practice

Board-Certified pharmacists are eligible to receive up to 6.0 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.



ASHP is approved by BPS as a provider for the recertification of BCPS.

Learning Activity

Passing Score

Credit Information

The Aspirin Revolution Continues: Evaluating the Risks and Benefits of Aspirin Across the Spectrum of Cardiovascular Disease

63%

1.5 Contact Hours

BPS: BCPS
ACPE: 0204-0000-24-237-H01-P

Generative Artificial Intelligence: Benefits and Pitfalls

80%

2.0 Contact Hours

BPS: BCPS
ACPE: 0204-0000-24-256-H99-P

Clearing the Air: COPD Management Strategies

66%

1.5 Contact Hours

BPS: BCPS

ACPE: 0204-0000-24-326-H01-P

Do You Have a NonINFERIORITY (Trial) Complex?

66%

1.0 Contact Hours

BPS: BCPS
ACPE: 0204-0000-24-347-H99-P

The Aspirin Revolution Continues: Evaluating the Risks and Benefits of Aspirin Across the Spectrum of Cardiovascular Disease
ACPE #: 0204-0000-24-237-L01-P

  • Evaluate the role of aspirin in patients with transient ischemic attack and stroke.
  • Discuss the role of aspirin in patients with peripheral arterial disease.
  • Recommend an antithrombotic therapy regimen optimizing bleeding and thrombosis prevention in patients with chronic coronary disease. 

Generative Artificial Intelligence: Benefits and Pitfalls
ACPE #: 0204-0000-24-256-L99-P

  • Describe generative AI and large language models.
  • Assess ways generative AI can be used in clinical practice.
  • List best practices for prompt engineering. 

Clearing the Air: COPD Management Strategies
ACPE #: 0204-0000-24-326-L01-P

  • Summarize the latest COPD guideline updates.
  • Evaluate the evidence to support the latest COPD updates and pharmacotherapies.
  • Design an appropriate therapeutic regimen for the management of acute and chronic COPD utilizing patient-specific factors. 

Do You Have A NonINFERIORITY (Trial) Complex?
ACPE #: 0204-0000-24-347-L99-P

  • Compare and contrast noninferiority, superiority, and equivalence trial designs.
  • Summarize the limitations and uses of noninferiority trial design.
  • Analyze noninferiority study methodology and results of a clinical trial using a noninferiority study design.

Faculty bios

Christopher Betz, PharmD, BCPS, FASHP, FKSHP
Clinical Pharmacist Practitioner – Cardiology/Pharmacogenomics
Louisville VA Medical Center

Emily Frederick, PharmD, BCPS
Associate Professor and Director of Student Affairs
Sullivan University College of Pharmacy & Health Sciences

Snehal H. Bhatt, PharmD, BCPS-AQ Cardiology, FASHP, AACC
Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences

Lourdes Cross, PharmD, BCACP, CDCES
Associate Professor
Sullivan University College of Pharmacy and Health Sciences 

Yaa Kumah-Crystal, MD, MPH, MS
Assistant Professor
Vanderbilt University Medical Center

Elyse MacDonald, PharmD, MS, BCPS
Director of Pharmacy
Investigational Drug Service and Oncology Infusion Pharmacy
Stanford Health Care

Scott D. Nelson, PharmD, MS, FAMIA, ACHIP
Associate Professor, Biomedical Informatics
Vanderbilt University Medical Center

Maria Shin, PharmD, BCGP, BCPS
Clinical Pharmacist Practitioner, Internal Medicine
Robley Rex VA Medical Center

Sue Dombrowski, MS, RPh
Christopher Betz, PharmD, BCPS, FASHP, FKSHP*
Snehal Bhatt, PharmD, AACC, BCPS-AQ Cardiology, FASHP*
Benjamin Michaels, PharmD, ACE*
Brooklyn Olumba, PharmD, BCPS*

*Content Matter Experts

Ally Bergman, PharmD, BCPS
Anthony Bolson, PharmD, BCPS
Tara Breuer, RPh, BCPS, BCSCP
Amber Carter, PharmD, BCPS
Fiona Chao, PharmD, BCPS, AAHIVP
Allison Cone, PharmD, BCPS, BCOP
Katherine Conway, PharmD, BCPS
Ashley Crouch, PharmD, BCPS
Rachel DiNino, PharmD, BCPS, BCSCP
Amy Eliason, PharmD, BCPS
Ariel Foster, PharmD BCPS
Miranda Fuller, PharmD, BCPS, BCIDP
Allison Gorseth, PharmD, BCPS
Allyson Helms, PharmD, BCPS, BCACP, MS HSPA
Ashly Ibrahim, PharmD, BCPS
Andrea Lippucci, PharmD, BCPS, BCOP
Ashley Lock, PharmD, BCPS, BCEMP
Alexa Maisenbach, PharmD, BCPS
Amanda Meyer, PharmD, MBA, BCPS
Anne Muhleisen, PharmD, BCPS
Rachel Nealon, PharmD, BCPS
Bambi Randall, PharmD, BCPS
Allen Robinson, Pharms, BCPS
Alli Rosa, PharmD, MBA, BCPS, BCCCP
Anastasiya Shor, PharmD, BCPS
Anh Tang, PharmD, BCPS
Arlene Thomas, PharmD, BCPS
Allie Torrence, PharmD, BCPS
Alyssa  Trenkle, PharmD, BCPS
Tayyiba Turzhitsky, PharmD, BCPS
Tyler Vest, PharmD, MS, BCPS, BCSCP, FNCAP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following person in control of this activity’s content has relevant financial relationships:

  •          Snehal Bhatt –Consultant and Speaker’s Bureau: Janssen Pharmaceuticals, Inc.

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations.  Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP.